Shingles Vaccine Slashes Heart Risk by Nearly Half
A landmark study of nearly 250,000 U.S. adults with heart disease found that shingles vaccination reduced major cardiac events by 46% and all-cause mortality by up to 66% within one year, rivaling the cardiovascular benefit of quitting smoking.
A Surprising Shield for the Heart
A vaccine designed to prevent a painful skin rash may be one of the most powerful cardiovascular protections available today. A major new study presented at the American College of Cardiology's Annual Scientific Session (ACC.26) in New Orleans found that people with heart disease who received a shingles vaccine were 46% less likely to suffer a serious cardiac event and 66% less likely to die from any cause within a year, compared with unvaccinated patients.
The findings, led by Dr. Robert Nguyen, a resident physician at the University of California, Riverside, add to a growing body of evidence that the herpes zoster vaccine delivers benefits far beyond preventing shingles.
Inside the Numbers
Researchers analyzed electronic health records of 246,822 U.S. adults aged 50 and older diagnosed with atherosclerotic cardiovascular disease — the buildup of fatty plaque in arteries that drives most heart attacks and strokes. Half had received at least one dose of either the Shingrix or older Zostavax vaccine between 2018 and 2025; the other half had not been vaccinated.
After matching the groups on demographics and health conditions, the results were striking:
- 46% lower risk of major adverse cardiac events (MACE)
- 66% lower risk of death from any cause
- 32% lower risk of heart attack
- 25% lower risk of stroke
- 25% lower risk of developing heart failure
"This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke and death," Dr. Nguyen said. He noted that protective effects "might be even greater" in high-risk populations with existing cardiovascular disease than in the general public.
Why Would a Shingles Vaccine Protect the Heart?
The connection lies in the virus itself. Herpes zoster — the reactivation of the chickenpox virus lying dormant in nerve cells — does not just cause a painful rash. Research shows that shingles infections trigger inflammation and blood clot formation near the brain and heart, significantly raising the risk of heart attack and stroke.
By preventing shingles outbreaks, vaccination may block this cascade of vascular damage. A 2025 study published through the European Society of Cardiology found that shingles vaccination reduced cardiovascular event risk by 23% in the general population, with protection lasting up to eight years.
A Benefit Rivaling Quitting Smoking
Researchers have compared the magnitude of protection to one of medicine's gold-standard interventions: smoking cessation. Cardiovascular disease remains the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Finding a simple, widely available intervention with this scale of impact is exceptionally rare.
The study does have limitations. Its retrospective, observational design means it cannot definitively prove the vaccine causes better heart outcomes. It is possible that people who seek vaccination are generally healthier or more proactive about their health. The follow-up was also limited to the first year after vaccination.
What This Means Going Forward
Despite those caveats, the consistency of findings across multiple large studies — in general populations, diabetic patients, people living with HIV, and now high-risk cardiac patients — makes the signal difficult to dismiss. Experts say randomized controlled trials will be needed to confirm the link, but the evidence is already strong enough to reinforce existing recommendations.
For the roughly one in three people who will develop shingles in their lifetime, the vaccine already offers clear benefits. This research suggests the payoff may extend well beyond the skin — straight to the heart.
